HROWHealthcare · Drug Manufacturers - Specialty & GenericThe 9 Wall Street analysts covering Harrow, Inc. hold a median 12-month price target of $60 — +119.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 17 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Harrow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HROW, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +119.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | BTIG | Reiterates | Buy | $63 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $45 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $63 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | — |
| 21 July 2026 | BTIG | Reiterates | Buy | $63 |
| 21 July 2026 | BTIG | Reiterates | Buy | — |
| 13 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 13 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $91 → $88 |
| 12 May 2026 | BTIG | Reiterates | Buy | $63 |
| 12 May 2026 | BTIG | Reiterates | Buy | — |
| 17 Apr 2026 | BTIG | Reiterates | Buy | — |
| 7 Apr 2026 | B. Riley Securities | Reiterates | Buy | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Mar 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Nov 2025 | Ladenburg Thalmann | Maintains | Buy | — |
| 1 Oct 2025 | B. Riley Securities | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HROW appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Harrow, Inc. returned −28.1% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 30% of US stocks
Cheaper than 2% of US stocks
Cheaper than 3% of US stocks
Higher than 55% of US stocks
Higher than 49% of US stocks
Higher than 84% of US stocks
Higher than 22% of US stocks
Higher than 18% of US stocks
Higher than 12% of US stocks
Higher than 42% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Harrow, Inc. has a market value of $1.1B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $275.6M. The latest quarter grew 10.9% year on year.
Net income over the same four quarters: −$37.2M, a −13.5% net margin.
Diluted earnings per share, trailing twelve months: $−1.00.
Free cash flow in the twelve months to 30 June 2026: −$13.1M.
Trailing P/E: −205.6×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Harrow, Inc. employs 373 people — $739K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Harrow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted recent movements in the options market for Harrow (HROW), saying investors should pay close attention to the stock.
Why it matters — HROW watchers may want to note the recent options-market activity, though the excerpt provides no details about its direction or implications.
Seeking Alpha says Harrow’s full-year guidance requires a strong second half, with Q3 and Q4 needing record-high revenue and positive EBITDA after H1 revenue targets were missed. It notes improved Q3 tailwinds from VEVYE payer coverage, better IHEEZO pricing and reimbursement, and the TYRVAYA acquisition.
Why it matters — Harrow watchers will be looking to Q3 results to assess whether the company can deliver the performance its full-year guidance requires.
Harrow, Inc. announced it has completed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease. The product adds a differentiated, drop-free treatment option to Harrow's growing ocular surface franchise.
Why it matters — The acquisition expands Harrow's ocular surface product portfolio with a unique, FDA-approved nasal spray option, strengthening its position in the dry eye disease market.
Harrow announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at the AAOpt Annual Meeting in Anaheim and the AAO Annual Meeting in New Orleans in fall 2026.
Why it matters — The presentations highlight the breadth and scientific visibility of Harrow's ophthalmic portfolio at two major industry meetings, underscoring the company's position in ophthalmic disease management.
Harrow announced that its management will participate in three investor conferences in September in New York, NY, including the 2026 Cantor Global Healthcare Conference, scheduled for September 9, 2026, featuring a fireside chat and one-on-one investor meetings.
Why it matters — Investors following Harrow may be interested in the company's participation in these conferences as an opportunity for management to engage directly with the investment community.
The 9 Wall Street analysts covering Harrow, Inc. have a median 12-month price target of $60, with estimates ranging from $45 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Harrow, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harrow, Inc. 43 out of 100 across roughly 4,600 US stocks as at 17 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Oct 2026, Harrow, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +119.9% from the last close, and Ticker Nerd's factor model ranks Harrow, Inc. 43 out of 100 as at 17 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Harrow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HROW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $88 over the next 12 months.
Harrow, Inc. returned -28.1% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "Do Options Traders Know Something About Harrow Stock We Don't?". Zacks Investment Research highlighted recent movements in the options market for Harrow (HROW), saying investors should pay close attention to the stock.
Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.
CEO Mr. Mark L. Baum J.D. · 373 employees · United States · https://www.harrow.com
